Valneva SE (NASDAQ:VALN) is one of the most undervalued biotech stocks to buy right now. Guggenheim cut the price target on Valneva SE (NASDAQ:VALN) to $11 from $13 on April 16, reiterating a Buy ...

Valneva shares hit €2.34 low as Goldman Sachs downgrades to Sell, citing failed Lyme trial and Chikungunya withdrawal, though Pfizer partnership and European sales offer hope.

FILE PHOTO: The logo of French-Austrian biotech firm Valneva is seen outside their headquarters in Vienna, Austria, December 16, 2021. REUTERS/Lisi Niesner/File Photo Jan 19 (Reuters) - French ...

In this article, we will look at the 8 Most Undervalued Biotech Stocks to Buy Right Now. On April 13, Tom Lee, Fundstrat’s head of research, appeared on CNBC’s ‘Power Lunch’ to talk about his outlook ...

VIENNA, Austria, March 18, 2026 /PRNewswire/ -- Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced an exclusive ...

Valneva (VALN) and the world’s largest vaccine maker, Serum Institute of India, announced on Wednesday that they have mutually agreed to discontinue their licensing agreement for the former’s ...

Valneva's shares are trading near a 52-week low of €2.37, having shed roughly 38% since the start of the year. This stark decline reflects the high-stakes balancing act the French biotech now faces, ...

Pharmaceutical giant Pfizer PFE1.24%increase; green up pointing triangle and French vaccine maker Valneva VLA-3.34%decrease; red down pointing triangle reported positive topline results from their ...

Valneva SE (NASDAQ:VALN) is one of the most undervalued biotech stocks to buy right now. Guggenheim cut the price target on Valneva SE (NASDAQ:VALN) to $11 from $13 on April 16, reiterating a Buy ...